Novartis Files Judicial Review against Avastin

.

Novartis Files Judicial Review against Avastin

It has been recently revealed that some local health authorities in the south of England are using economic eye drop, known as Avastin, for the wet age-related macular degeneration (AMD) problem. The drug is in fact not licensed for eye use, and has raised concerns among the authorities concerned.

As soon as Swiss drug maker Novartis got to know about the issue, which provides eye drug known as Lucentis in Britain, they are spreading the difference between the two and have been challenging the cheap alternative.

Lucentis is approved by the National Institute for Health and Clinical Excellence, and has been recommended by all doctors. Its annual sales for Novartis are about $2 billion, said experts, who have been raising concerns about the cheap alternative.

It is suspected that the drug Avastin does not cost much and this is the reason that it is given to people, who cannot afford expensive medicines for eyes. Experts are of the view that the cheap alternative is not even recommended by the National Institute for Health and Clinical Excellence.

Novartis said that they are going to initiate a judicial review of the policy in Southampton, Hampshire, Isle of Wight and Portsmouth, and trying their best that people stop taking such cheap alternatives. They further affirmed that people are just thinking about the cost, and are not thinking about the harm they are doing to their eyes.

“It is unacceptable to put the safety of patients at risk through the widespread use of an unlicensed treatment when a licensed medicine is available”, said Novartis. However, industry experts are of the view that companies like Novartis has not right to take decisions for other available drugs.


Latest News

Mylan says Speculations of an Acquisition by Teva is a Rumour
Higher Gasoline Prices Lifts US Consumer Prices in March
Ahead of Apple’s Announcement of Earnings Report Analysts Forecast the Success R
Another Round of Layoff Announced by Schlumberger Cutting 11,000 jobs
Mattel and Quirky Unveil a Partnership to Create New Toys from Crowd Source
Washington Firms Hauling Greater Venture Capital Funds
The Foreclosure Activities in March Rise Sharply in the U.S
Slowdown in U.S. Crude Production Inches Brent crude Prices Higher
Japan Surpasses China as the Largest U.S. Bonds Holder
In a $2.5 Billion Deal, China’s Alibaba Injects Pharmacy Business into affiliate
Union Spends Huge Money for Low-Wage Campaign but Organizing Fast Food Workers i
Beijing Should Find the Right Mix of Policies to Perk up Growth